Implementing a Clinical Immunogenicity Strategy using Preclinical Risk Assessment Outputs.

Area of Science:

• Biopharmaceutical Development
• Immunology
• Risk Assessment

Background:

• Immunogenicity to biologic drugs is a frequent challenge in clinical trials, influenced by both product characteristics and host factors.
• Predicting clinical immune responses remains difficult due to the complex immune system and patient variability, despite risk factor identification.
• Current methods for identifying and mitigating immunogenicity risks prior to human trials are essential but have limitations.

Purpose of the Study:

• To provide an overview of recent advancements in preclinical risk assessment approaches for biologic drug development.
• To highlight how these tools can aid in selecting candidates with lower immunogenicity risk.
• To guide the development of effective clinical bioanalytical and immunogenicity monitoring strategies.

Main Methods:

• Review of current preclinical risk assessment tools and methodologies for evaluating immunogenicity.
• Discussion of systematic approaches for identifying and mitigating potential immunogenic risks.
• Exploration of integrating pharmacogenomics and patient-specific factors into risk assessment.

Main Results:

• Advanced risk assessment tools can help rank biologic candidates based on their likelihood of eliciting an immune response.
• Outputs from these tools can inform the development of tailored clinical immunogenicity monitoring plans.
• A structured roadmap for performing risk assessments and their documentation for regulatory submissions is proposed.

Conclusions:

• Systematic preclinical risk assessment is vital for optimizing biologic drug development and minimizing clinical immunogenicity.
• Proactive risk assessment and mitigation strategies can streamline regulatory processes and personalize patient outcomes.
• Recommendations are provided for incorporating robust risk assessment components into Investigational New Drug (IND) applications and Integrated Summaries of Immunogenicity.